Aspire-lakewood Holdings, Inc.

Aspire-lakewood Holdings, Inc. (ASBP) Stock Analysis

$8.055

+1.543 (+19.16%)At close

Loading chart…
High
8.320
Open
6.730
VWAP
7.69
Volume
29.86K
Mkt Cap
—
Low
6.700
Amount
229.71K
EV/EBITDA, TTM
0.00

Aspire-Lakewoood Holdings, Inc., formerly Aspire Biopharma Holdings, Inc., through its subsidiary, Dura Control Systems Corp. (DCSC), is a designer and manufacturer of highly engineered automotive and industrial control systems that combine mechanical engineering, electronics and computer science to provide intelligent, automated systems for vehicle electrification, safety, lightweighting, and sustainability. DCSC maintains a powertrain agnostic product portfolio that includes mechatronic actuators, human machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates 11 manufacturing facilities globally and serves as a tier one automotive supplier to major OEMs and other industrial firms. The Company also engages in the business of developing and marketing disruptive technology for novel sublingual delivery mechanisms initially for known drugs and supplements, such as aspirin and caffeine products.

AI analysis of Aspire-lakewood Holdings, Inc. (ASBP)

Hold

Currently, PowerUp Acquisition Corp (ASBP) is not a strong buy. The stock is trading at $8.06, which is significantly down 95.10% year-to-date and 95.65% over the past year. The RSI is at 55.053, indicating a neutral momentum, while the forward P/E is 0, suggesting no earnings growth expectations. The stock has a gross margin of 20.28% for Q1 2026, but it also reported a net income loss of $3,222,892 in the same quarter. The main risk is the high volatility and historical performance, with a 52-week high of $372.00 and a low of $3.31, indicating potential instability in price.

Valuation Metrics

The current forward P/E ratio for Aspire-lakewood Holdings, Inc. (ASBP) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for ASBP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ASBP

$0.44

Scenario price

B

Base

Base · 50%ASBP

$0.38

Scenario price

B

Bear

Bear · 25%ASBP

$0.32

Scenario price

Whales holding ASBP

V

VR Advisory Services Ltd.

+ HoldingASBP

+0.00%

3M Return

Events Timeline

2026-09-09 (ET)

09:00:00

Aspire-Lakewood Authorizes $10M Stock Repurchase Program

2026-08-10 (ET)

09:00:00

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems

2026-07-29 (ET)

12:30:00

Aspire Biopharma Holdings Inc Trading Halted

2026-07-20 (ET)

09:00:00

Aspire Biopharma Appoints Jarryd McNeil as BUZZ BOMB Sponsored Athlete

2026-06-12 (ET)

14:30:00

Aspire Biopharma Holdings Inc Trading Halted

News

ASBP FAQ — answered by Alphio AI

Aspire-Lakewoood Holdings, Inc., formerly Aspire Biopharma Holdings, Inc., through its subsidiary, Dura Control Systems Corp. (DCSC), is a designer and manufacturer of highly engineered automotive and industrial control systems that combine mechanical engineering, electronics and computer science to provide intelligent, automated systems for vehicle electrification, safety, lightweighting, and sustainability. DCSC maintains a powertrain agnostic product portfolio that includes mechatronic actuators, human machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates 11 manufacturing facilities globally and serves as a tier one automotive supplier to major OEMs and other industrial firms. The Company also engages in the business of developing and marketing disruptive technology for novel sublingual delivery mechanisms initially for known drugs and supplements, such as aspirin and caffeine products. It operates in the Healthcare sector.

Currently, PowerUp Acquisition Corp (ASBP) is not a strong buy. The stock is trading at $8.06, which is significantly down 95.10% year-to-date and 95.65% over the past year. The RSI is at 55.053, indicating a neutral momentum, while the forward P/E is 0, suggesting no earnings growth expectations. The stock has a gross margin of 20.28% for Q1 2026, but it also reported a net income loss of $3,222,892 in the same quarter. The main risk is the high volatility and historical performance, with a 52-week high of $372.00 and a low of $3.31, indicating potential instability in price.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading